This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in Pneumocystis pneumonia폐포자충 폐렴을 유발한 HIV 감염병 (HIV 폐포자충폐렴)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: B20.6 (HIV disease resulting in Pneumocystis pneumonia) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration)
B. SynonymsHIV Pneumocystis pneumonia, HIV PCP, HIV-associated PCP, Pneumocystis jirovecii pneumonia, former name: Pneumocystis carinii pneumonia, AIDS-defining PCP, HIV-associated Pneumocystis pneumonia
C. Adult onsetLikelihood of first onset in adulthood: very high — AIDS-related PCP overwhelmingly occurs in adult HIV patients with CD4 <200/μL and was the most common cause of AIDS-defining illness in the pre-ART era. Neonatal and pediatric PCP differ pathophysiologically.
1. HistoryFirst described in 1942 as interstitial plasma cell pneumonia in children → named Pneumocystis carinii in 1951 → cluster outbreak in gay men in the United States in 1981 → first official description of AIDS → preventive effect of TMP-SMX established in 1989 → reclassified in 2001 as the human-specific species P. jirovecii → incidence fell sharply after ART in 1996 → latest revision of DHHS guidelines in 2023.
2. CausesCausative organism: Pneumocystis jirovecii (human-specific non-culturable fungus; found worldwide, airborne transmission). Pulmonary reactivation or reinfection at CD4 <200/μL. Non-HIV: also occurs in patients on steroids, immunosuppressants, with hematologic malignancy, organ transplantation, or anticancer therapy. In HIV, CD4 below 200/μL is the strongest risk factor.
3. GeneticsIL-12RB1, GATA2 mutations → impaired fungal immunity. Reduced MHC II-associated antigen presentation in HIV patients. P. jirovecii cannot be cultured → genomic studies use metagenomic methods. DHPS (dihydropteroate synthase) mutations → associated with TMP-SMX resistance. Human IFN-γ susceptibility polymorphisms influence predisposition to PCP.
4. General epidemiologyBefore ART: 60–80% of HIV patients experienced PCP in their lifetime. Number 1 cause of AIDS-defining illness. After ART + TMP-SMX prophylaxis: incidence reduced by 90%. In developed countries, PCP now occurs mainly in patients before HIV diagnosis or in those who discontinued or were non-adherent to ART. Worldwide, more than about 400,000 people per year are hospitalized with immunosuppression-related PCP.
5. Epidemiology in KoreaKDCA HIV/AIDS notification data: PCP ranks 1st–2nd among causes of AIDS-defining illness in Korea. Despite improved ART treatment rates, patients with late HIV diagnosis (CD4 <200/μL) account for 30–40% of new cases, so a PCP risk group persists. At HIV-dedicated hospitals in Korea, PCP is a leading cause of admission. Case reports of atovaquone or pentamidine use in patients allergic to TMP-SMX.
6. PathophysiologyP. jirovecii trophic form → attachment to alveolar epithelial cells (type I alveolar cells, SP-A/SP-D receptors) → cyst (cyst/ascus) formation → release of many trophic forms. Decreased CD4 T-cell function → absence of alveolar macrophage and CD8 cytotoxic T-cell responses → overgrowth of P. jirovecii in the alveoli → impaired gas exchange → elevated LDH · hypoxemia. The inflammatory response paradoxically also contributes to lung injury (this is the rationale for adjunctive steroid therapy).
7. Clinical featuresSubacute course (progressing slowly over several weeks): fever, dry cough (no sputum), dyspnea (on exertion → at rest). Chest X-ray: bilateral interstitial opacities (bat-wing or perihilar). Chest CT: bilateral ground-glass opacity — highly characteristic. Auscultation: normal or fine crackles. Elevated LDH (highly sensitive but nonspecific). Spontaneous pneumothorax may complicate. SpO₂ normal at rest but decreases on exertion (desaturation).
8. Tests and diagnosisBronchoalveolar lavage (BAL) GMS or IF staining or PCR: definitive diagnosis. Induced sputum immunofluorescence staining (sensitivity 50–90%). Serum β-D-glucan test: sensitivity over 90%, high negative predictive value. Chest HRCT: bilateral GGO. PaO₂ <70mmHg (or A-a gradient >35mmHg) → severe criterion → indication for adjunctive steroid therapy.
9. TreatmentFirst line: TMP-SMX (trimethoprim-sulfamethoxazole) 15–20mg/kg/day (as TMP) in 3–4 divided doses, 21 days. Severe (PaO₂ <70mmHg): adjunctive steroids — prednisolone 40mg twice daily for 5 days → 40mg/day for 5 days → 20mg/day for 11 days. TMP-SMX intolerance: atovaquone, primaquine + clindamycin, IV pentamidine. ART: starting ART within 2 weeks after beginning TMP-SMX treatment is recommended.
10. PrognosisWith appropriate treatment, mortality 10–25% (severe). Before ART, 60% of survivors of the first episode relapsed within 1 year. With ART + TMP-SMX prophylaxis, the relapse rate is <5%/year. Severe PCP (requiring mechanical ventilation): mortality 40–60%. CD4 recovery (>200/μL) + viral suppression: prophylactic medication can be stopped. PCP worsening after IRIS (rare but exists).
11. Latest findingsDHHS 2023 guidelines: in patients allergic to TMP-SMX, rechallenge after graded desensitization is recommended. Increasing reports of potential TMP-SMX resistance due to P. jirovecii DHPS mutations (limited clinical impact). Research on BAL-avoidance algorithms using the negative predictive value of the β-D-glucan test is active. With the rise of non-HIV PCP (hematologic malignancy, biologic agents), prophylaxis guidelines are being reconsidered for HIV-uninfected immunocompromised hosts as well.
12. PreventionPrimary prophylaxis: TMP-SMX DS 1 tablet/day (or SS 1 tablet/day) — start when CD4 <200/μL or with oropharyngeal candidiasis/AIDS-defining illness. CD4 of 200/μL or more sustained (3 months or longer) + viral suppression → prophylaxis may be stopped. Alternatives: atovaquone 1,500mg/day, dapsone 100mg/day, aerosolized pentamidine 300mg/month. TMP-SMX also simultaneously prevents toxoplasmosis and some bacterial infections.
13. ReferencesHuang L et al. HIV-associated Pneumocystis pneumonia and 9 other papers

1. History

Pneumonia due to Pneumocystis was first described by van der Meer and Brug in 1942 in the Netherlands as interstitial plasma cell pneumonia occurring in premature infants and malnourished children. In 1951, Vaněk and Jírovec named the causative pathogen Pneumocystis carinii (applying to humans a species name originally described in rat lungs). Thereafter it was reported sporadically, mainly in starving children during wartime and in immunodeficient children.

The turning point was 1981. The US CDC reported in the MMWR a cluster outbreak of P. carinii pneumonia (PCP) in five previously healthy young gay men in Los Angeles. This was the first official description of HIV/AIDS. PCP became established as the most common initial manifestation of AIDS-defining illness, and in the 1980s 60–80% of AIDS patients experienced PCP at least once in their lifetime.

Bozzette et al. in 1989 established the efficacy of TMP-SMX for primary prevention of PCP in a randomized controlled trial, and TMP-SMX prophylaxis subsequently became standard. Stringer et al. in 2001 proved by genetic analysis that human Pneumocystis is a species distinct from rat P. carinii and renamed it Pneumocystis jirovecii (named in honor of the Czech parasitologist Otto Jirovec). After the introduction of ART in 1996, the incidence of PCP fell by more than 90%.

2. Causes

Pneumocystis jirovecii is a human-specific non-culturable fungus with polymorphism. Morphologically, two forms exist: the trophic form (1–4μm) and the cyst (cyst/ascus, 5–8μm). Each cyst contains eight intracystic bodies, which are released as trophic forms after the cyst matures and ruptures.

P. jirovecii cannot be cultured artificially, and short-term proliferation is possible only in cell-line culture systems. Transmission is via airborne droplets, and most healthy children experience infection (seroconversion) within the first few years of life. It remains latent in immunocompetent individuals and is reactivated when the CD4 count falls or in other immunosuppressed states.

Risk factors

In the ART era, PCP in HIV patients occurs mainly in patients unaware of their HIV diagnosis or patients who stopped ART or interrupted it.

3. Genetics

Because P. jirovecii cannot be cultured, genetic analysis relies mainly on metagenomic methods and direct sequencing of BAL specimens. The complete genome sequence of P. jirovecii was published in 2020, and a unique cell wall synthesis pathway (1,3-β-glucan synthase FKS gene) and dependence on lipid metabolism were identified.

DHPS (dihydropteroate synthase) gene mutations (A55V, T57I, P57S): mutations of the target enzyme of TMP-SMX, emerging through selection pressure in patients exposed to TMP-SMX during prophylaxis. The proportion of DHPS-mutant strains is increasing in Europe and North America, but an association with clinical TMP-SMX treatment failure has not yet been established.

Host genetics: studies suggest that polymorphisms of SP-A, SP-D (pulmonary surfactant proteins) influence susceptibility to PCP. Cases of PCP have been reported in patients with primary immunodeficiency carrying IL-12RB1 and GATA2 mutations.

4. General epidemiology

In the pre-ART era (1981–1996), PCP was the most common cause of AIDS-defining illness, and 60–80% of HIV patients experienced it at least once in their lifetime. In the late 1980s in the United States, about 20,000 HIV patients per year died of PCP.

The combination of TMP-SMX prophylaxis introduced in 1989 and ART in 1996 reduced incidence by more than 90%. In the United States, PCP hospitalizations decreased from about 70,000 in 1995 to about 9,000 in 2009. However, non-HIV PCP is also on the rise owing to ART non-adherence, late diagnosis, and increased use of new immunosuppressive drugs (rituximab, etc.).

Worldwide, PCP remains an important opportunistic infection in immunocompromised patients and is still one of the leading causes of AIDS death in HIV patients in low-income countries. High incidence persists in regions lacking universal access to CD4 count measurement and TMP-SMX prophylaxis.

5. Epidemiology in Korea

In HIV patients in Korea, PCP consistently ranks 1st–2nd among causes of AIDS-defining illness. According to KDCA HIV/AIDS notification and university hospital cohort data, the rate of PCP co-occurrence at the time of AIDS diagnosis reaches 20–30%. Although the ART treatment rate in Korea has improved to over 90% in the 2020s, late HIV diagnosis (late presenter) accounts for 30–40% of new infections, and the PCP risk is high when these individuals are first diagnosed with CD4 <200/μL.

PCP is reported as the most common AIDS opportunistic infection cause of admission in analyses of admissions to HIV-dedicated hospitals in Korea. Cases using atovaquone or aerosolized pentamidine have been reported in Korean patients with TMP-SMX allergy, and prevention and treatment strategies in such patients are clinically important.

Non-HIV PCP is also increasing in Korea, and TMP-SMX prophylaxis is recommended especially for hematologic malignancy patients using rituximab, ibrutinib, or BTK inhibitors and for autoimmune disease patients on high-dose steroid therapy.

6. Pathophysiology

Pathogen proliferation in the lung

P. jirovecii trophic forms attach by binding to vitronectin, fibronectin, SP-A, and SP-D receptors on the surface of alveolar type II and type I cells. The trophic forms divide and proliferate and then form cysts (diameter 5–8μm), repeating a life cycle in which the eight internal trophic forms mature and are released.

Immune defense mechanisms and their collapse in HIV

In normal immunity, alveolar macrophages, CD4+ T cells (Th1 response, IFN-γ secretion), and CD8+ cytotoxic T cells cooperate to suppress P. jirovecii in the lung. When CD4+ T cells decline below 200/μL because of HIV infection, this defense mechanism collapses and P. jirovecii overgrows in the alveoli.

Mechanism of lung injury

The organism itself and the host inflammatory response together cause alveolar injury. Overgrown P. jirovecii fills the alveolar spaces and damages alveolar epithelial cells, resulting in impaired oxygen–carbon dioxide exchange. At the same time, an excessive inflammatory response (cytokine storm) by macrophages and CD8+ T cells worsens alveolar injury. This paradoxical inflammatory response is the rationale for adjunctive steroid therapy (improved prognosis in severe PCP). Elevated LDH is an indicator of lung epithelial cell injury.

Spontaneous pneumothorax

Alveolar rupture during the course of PCP can cause spontaneous pneumothorax (frequency about 2–5%). The risk increases especially when upper lobe predominant involvement appears during aerosolized pentamidine prophylaxis.

7. Clinical features

In HIV patients, PCP generally shows a subacute onset and progresses slowly over several weeks. In non-HIV immunosuppressed patients, it presents more acutely and rapid respiratory failure may occur.

Classic triad of symptoms

Fever, dry cough (nonproductive cough), and exertional dyspnea are the typical triad of symptoms. Dyspnea occurring initially only on exertion progresses to occur at rest as well. In severe cases, hypoxemia presents as decreased SpO₂ and cyanosis.

Physical examination

Auscultation is usually normal or fine crackles are heard. Unlike bacterial pneumonia, percussion is normal and high-pitched crackles are uncommon. Exertional desaturation: even if SpO₂ is normal at rest, a drop in SpO₂ of 3–5% or more after walking for several minutes should strongly raise suspicion of PCP.

Imaging findings

Chest X-ray: bilateral symmetric interstitial or alveolar opacities (perihilar bat-wing pattern). Normal findings are also possible early on (10–20%). Chest HRCT is much more sensitive, and bilateral ground-glass opacity is characteristic. Upper lobe predominance (especially after aerosolized pentamidine prophylaxis), cystic lesions, and spontaneous pneumothorax may accompany.

Laboratory findings

Elevated serum LDH (>1.5–2 times normal): sensitivity over 90% but low specificity. Decreased S-adenosylmethionine (SAM) has also been reported. Elevated blood beta-D-glucan (sensitivity over 95%). Arterial blood gas: hypoxemia (PaO₂ <70mmHg), respiratory alkalosis (decreased PaCO₂ due to hyperventilation), increased A-a gradient.

8. Tests and diagnosis

Confirmatory tests

Bronchoalveolar lavage (BAL): standard for diagnosis. BAL fluid is stained with Gomori methenamine silver (GMS), calcofluor white, Giemsa, or direct fluorescent antibody (DFA) to identify trophic forms or cysts. Sensitivity 90–99%, specificity 98–100%. PCR is also possible with higher sensitivity but requires differentiation from colonization.

Induced sputum: noninvasive method. Sputum is induced by inhaling hypertonic saline, followed by DFA staining. Sensitivity 50–90% (varies with facility and technician capability).

Serum beta-D-glucan

Beta-D-glucan is a component of the P. jirovecii cell wall and is markedly elevated in PCP (usually >80 or >100 pg/mL). Sensitivity over 95% and a very high negative predictive value, so a negative result makes PCP unlikely. However, beware of false positives (other fungal infections, albumin administration, some antibiotics). Algorithm studies are active on deciding empirical treatment without BAL using a combination of imaging and β-D-glucan.

Severity assessment

Arterial blood gas test: PaO₂ <70mmHg or A-a gradient >35mmHg → severe criterion → indication for adjunctive steroid therapy. Mild to moderate: PaO₂ ≥70mmHg, SpO₂ ≥92%.

9. Treatment

First-line treatment: TMP-SMX

Trimethoprim-sulfamethoxazole (TMP-SMX): 15–20mg/kg/day as TMP, 75–100mg/kg/day as SMX. Given in four divided doses intravenously (severe) or orally (mild). Treatment duration 21 days. TMP-SMX is the most effective PCP treatment, dually blocking the folate metabolic pathway (inhibiting DHPS + DHFR). Adverse effects: rash and hypersensitivity reactions (10–20%), neutropenia, hepatotoxicity, electrolyte abnormalities (hyperkalemia), nephrotoxicity.

Adjunctive steroid therapy

Severe criteria (PaO₂ <70mmHg or A-a gradient >35mmHg): prednisone (prednisolone) 40mg twice daily × 5 days → 40mg/day × 5 days → 20mg/day × 11 days (21 days total). Steroids are started within 72 hours of the start of PCP treatment, preferably at the same time. Effect in reducing mortality and respiratory failure has been demonstrated.

Alternatives for TMP-SMX intolerance

Timing of ART initiation

Start ART as soon as possible after the start of PCP treatment, within 2 weeks (START EARLY strategy). This is based on the results of the ACTG A5164 study showing that early ART initiation during PCP treatment benefits mortality reduction. Unlike cryptococcal meningitis, IRIS is relatively uncommon in PCP, so the need to delay ART is low.

10. Prognosis

With appropriate treatment and adjunctive steroid therapy, mortality in mild to moderate PCP is 5–10%. In-hospital mortality in severe PCP (requiring mechanical ventilation) is very high at 40–60%. In the pre-ART era, 60% of survivors of the first episode relapsed within 1 year, but with ART + TMP-SMX prophylaxis the relapse rate has fallen below 5%.

Poor prognostic factors: need for mechanical ventilation, pneumothorax, CD4 <50/μL, delayed treatment initiation, other concomitant opportunistic infections. If there is no clinical improvement within 4–5 days of treatment, reconsider the diagnosis (differentiate other lung infections) and consider changing treatment.

When CD4 of 200/μL or more is maintained and viral suppression is achieved after ART initiation, TMP-SMX prophylaxis can be safely stopped, and the subsequent risk of recurrence is very low.

11. Latest findings

The DHHS 2023 guidelines strongly recommend reuse of TMP-SMX after a graded desensitization protocol in patients allergic to TMP-SMX, because TMP-SMX is superior to alternative agents. Desensitization is performed in an outpatient or inpatient setting by gradually increasing from a low concentration over several hours to several days.

Potential TMP-SMX resistance due to DHPS mutations is increasing worldwide, but a clear causal relationship with clinical treatment failure has not been established to date. When there is clinical deterioration during treatment, it is important to differentiate other causes (bacterial superinfection, IRIS, resistance).

With the increase in non-HIV PCP (patients using B-cell-targeted therapies such as rituximab and ibrutinib), PCP prophylaxis guidelines for HIV-uninfected immunocompromised hosts are being reconsidered. Multicenter validation studies are ongoing of clinical algorithms that use the negative predictive value of beta-D-glucan to exclude PCP without BAL.

12. Prevention

Indications for primary prophylaxis

Start TMP-SMX prophylaxis if one or more of the following apply:

First-line prophylactic agents

TMP-SMX DS (double strength, 160/800mg) 1 tablet/day is the first choice. Alternatives: TMP-SMX SS (single strength, 80/400mg) 1 tablet/day or DS three times a week. TMP-SMX has the added benefit of simultaneously preventing Toxoplasma gondii (cerebral toxoplasmosis) and some bacterial infections (pneumococcus, some gram-negative bacteria). Adverse effects: rash, nausea, bone marrow suppression, hyperkalemia. Caution with dapsone in G6PD-deficient patients.

Alternative prophylactic agents

Criteria for stopping prophylaxis

If, after ART, the CD4 count remains at 200/μL or above for 3 months or longer and HIV RNA is suppressed, PCP prophylaxis can be safely stopped. If CD4 falls below 200/μL again or ART is stopped, prophylaxis must be restarted immediately.

Secondary prophylaxis (prevention of recurrence)

After completion of PCP treatment, maintenance prophylaxis with TMP-SMX (or an alternative) is continued as long as CD4 remains <200/μL. It can be stopped when CD4 of 200/μL or more is sustained + viral suppression is achieved (same as the criteria for stopping primary prophylaxis).


13. References

  1. Huang L, Cattamanchi A, Davis JL, et al. "HIV-associated Pneumocystis pneumonia." Proceedings of the American Thoracic Society. 2011;8(3):294-300. doi:10.1513/pats.201009-062WR
  2. Thomas CF Jr, Limper AH. "Pneumocystis pneumonia." New England Journal of Medicine. 2004;350(24):2487-2498. doi:10.1056/NEJMra032588
  3. Bozzette SA, Sattler FR, Chiu J, et al. "A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." New England Journal of Medicine. 1990;323(21):1451-1457. doi:10.1056/NEJM199011223232104
  4. Kovacs JA, Masur H. "Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment." JAMA. 2009;301(24):2578-2585. doi:10.1001/jama.2009.880
  5. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. "Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the NIH, and the HIV Medicine Association of the IDSA." MMWR Recommendations and Reports. 2009;58(RR-4):1-207. PMID:19357635
  6. Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. "Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the IDSA." Clinical Infectious Diseases. 2014;58(9):1308-1311. doi:10.1093/cid/ciu094
  7. Stringer JR, Beard CB, Miller RF, Wakefield AE. "A new name (Pneumocystis jiroveci) for Pneumocystis from humans." Emerging Infectious Diseases. 2002;8(9):891-896. doi:10.3201/eid0809.020096
  8. Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLOS ONE. 2009;4(5):e5575. doi:10.1371/journal.pone.0005575
  9. Panel on Opportunistic Infections in Adults and Adolescents with HIV. "Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Pneumocystis Pneumonia." AIDSinfo. 2023. clinicalinfo.hiv.gov
  10. Tasaka S, Tokuda H. "Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies." Journal of Infection and Chemotherapy. 2012;18(6):793-806. doi:10.1007/s10156-012-0453-0